calmette-guerin (BCG), immunogenic composition and use
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Dec 6, 2016
Issued Date -
N/A
app pub date -
Feb 18, 2013
filing date -
Feb 17, 2012
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
The present invention relates to recombinant Mycobacterium strain that encodes the mutated Escherichia coli LT heat-labile toxin or the A subunit of the mutated Escherichia coli LT heat-labile toxin. The present invention also relates to strains of Mycobacterium that encode the LT heat-labile toxin or the A subunit of the LT heat-labile toxin of Escherichia coli mutated in position 63. Specifically, the present invention relates to strains of Mycobacterium that encode the LT heat-labile toxin or the A subunit of the LT heat-labile toxin of Escherichia coli mutated in position 63 from serine to lysine. The present invention also provides immunogenic compositions that comprise the strains of the present invention. The present invention further provides for the use of said strains and immunological compositions in the production of a vaccine for preventing tuberculosis and infections caused by Mycobacterium tuberculosis. Lastly, the present invention relates to methods for preventing or treating tuberculosis in animals.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully